



PCOS Insight: Illuminating the Shadows


Shraddha Shrikant Kalamkar¹, Aasaware Mane²

UG Student¹, ² Mentor

Yadavrao Tasgaonkar Institute of Pharmacy

ABSTRACT :

Polycystic ovary condition is the most well-known endocrine problem in females of conceptive age, which is as yet serious. In any case, the side effects can be effectively dealt with legitimate drug and way of life mediations. Notwithstanding its predominance, little is had some significant awareness of its etiology. In this audit article, the forward-thinking symptomatic elements and boundaries suggested on the grounds of proof based information and various rules are investigated. The equivocalness and inadequacy of information while diagnosing young adult females have been put under extraordinary concentration. We take a gander at probably the latest examination done to lay out connections between various quality polymorphisms with polycystic ovary condition in different populaces alongside the misjudged effect of natural variables like endocrine-upsetting synthetic substances on the regenerative strength of these females. Moreover, the article closes with existing medicines choices and the degrees for headway soon. Different treatments have been considered as possible treatment through various randomized controlled examinations, and clinical preliminaries directed over the course of the years are depicted in this article. Standard treatments going from metformin to recently found options in view of vitamin D and stomach microbiota could focus some light and direction toward a long-lasting remedy for this female conceptive medical problem later on.



INTRODUCTION :

Polycystic ovary Syndrom (PCOS) is a broadly common metabolic and endocrine problem analyzed in regenerative matured females. The sickness is recognized by the presence and level of three significant highlights: sporadic monthly cycle, hyperandrogenism, and polycystic ovarian morphology (PCOM).

- 1] The commonness of PCOS is known to be around 5%-20%, contingent upon the changing definitions used.
- 2] Notwithstanding many advances and variations in fostering the demonstrative standards and deciphering the condition's pathophysiology, PCOS stays a less-grasped problem regarding models for uniform conclusion and treatment.
- 3] The complex impacts of the illness are spread across a lady's lifetime starting from origination and stretching out across the years following menopause.

4] A greater part of the examinations connected with PCOS were performed to foster an ideal and proficient determination, especially for youths, powerful therapy, and the executives of comorbidities related with PCOS that seriously influence the personal satisfaction, and a homogeneous convention that can be carried out by medical services officials.

5] In this survey, the symptomatic methodology and other screening conventions referenced were revolved around the latest global proof based rules for PCOS.

Besides, the article carefully described the conclusion of PCOS in grown-ups along with the difficulties looked in diagnosing juvenile young females. We have found an absence old enough unambiguous rules that is an outcome of deficient logical examinations. Moreover, the causal connections, both hereditary and natural, have been summed up with a short knowledge into the pathogenesis of PCOS. At last, the present status of the treatment is checked out, and the new choices with significant potential have been talked about.

The motivator to work with PCOS came from the comprehension that a specific level of females are as yet being misdiagnosed or passed on undiscovered because of ignorance and misconception. While chipping away at this article, it was clarified that numerous nations, particularly Bangladesh, are yet to genuinely take PCOS. This was shown through the absence of examination in these geological areas. In this way, we accept what is happening about the condition would assist with restricting the gorge in acknowledgment and make ready for improved replies.

PATHOPHYSIOLOGY AND RISK CONSIDERATIONS :

The undeniable element of this condition is the overflow of androgen found in PCOS patients. Hyperandrogenism is proven by raised degrees of free(unbound) testosterone in the circulatory system, a key chemical adding to the pathophysiology of PCOS. This perplexing condition is dismantled into its primary pathophysiological components . The inclining risk factors incorporate hereditary qualities, neuroendocrine, way of life/climate, corpulence that add to the improvement of Polycystic condition as portrayed in . A few females have a higher gamble of creating PCOS because of dominating qualities . A few information on extensive affiliation uncovered explicit loci and alleles that assume a significant part in PCOS aggregate distinguishing proof . Natural elements including actual activity, way of life, and food might shift generally as indicated by the populace . Ecological factors additionally incorporate endocrine-upsetting synthetic substances and glycotoxins that might cause hereditary fluctuation and disturbance of the metabolic and conceptive pathways, which can foster PCOS aggregates and related intricacies . Androgen openness can hinder the chemical levels to build the high heartbeat recurrence of GnRH influencing the LH: FSH extent and prompts follicular capture and dysplasia .

These elements lead to the reason for hyperinsulinemia, hyperandrogenism, oxidative pressure, unpredictable periods ultimately upsurging the metabolic condition. PCOS was named so on the grounds that it demonstrated different ovarian pimples (lacking follicles) on ultrasound assessment. The follicles advanced from crude follicles, yet because of disturbed ovarian capability, the improvement stopped at a beginning phase.

PCOS phenotype			
<i>Phenotype hormone</i>	<i>Without HA* + PCOS** (n = 100) mean ± SD</i>	<i>With HA + PCOS (n = 45) phenotype</i>	<i>p-value</i>
TSH	3.62 ± 1.90	3.36 ± 1.58	0.38
FSH	5.96 ± 2.34	6.43 ± 2.34	0.26
LH	12.63 ± 15.18	14.84 ± 10.66	0.37
PL	13.27 ± 4.85	13.12 ± 4.84	0.86
Testosterone	0.607 ± 0.35	0.655 ± 0.26	0.42
Free testosterone	1.47 ± 0.81	1.63 ± 0.57	0.22
DHEAS	2.15 ± 1.35	2.26 ± 1.24	0.62

Independent sample t-test—HA*: Hyperandrogenism; PCOS**: Polycystic ovarian syndrome; TSH: Thyroid stimulation hormone; FSH: Follicle stimulation hormone; LH: Luteinizing hormone; DHEAS: Dehydroepiandrosterone sulfate


PCOS AND HYPERANDROGENISM :

Weakened folliculogenesis is the consequence of surplus androgens that upset typical androgen union. The overabundance androgens advance the improvement of early stage follicles and expansion in the antral follicles at the early gonadotropin stage . The discharge of GnRH from the nerve center will initiate the gonadotropin chemical delivery from the pituitary. Luteinizing chemical actuates the LH receptor to advance androgen creation in ovarian theca cells, and the follicular animating chemical follows up on the FSH receptor all the while in the ovarian granulosa cells to change the androgens to estrogens, which advance the follicle development. . It has been expected that the dysregulation in the neuroendocrine framework brings about a lopsidedness of the hypothalamic-pituitary-ovarian hub prompting an excess degree of gonadotropin. The ascent in the GnRH advances the development of LH over FSH, bringing about an obvious hormonal expansion in the LH:FSH proportion in PCOS.

INSULIN OPPOSITION AND TYPE 2 DIABETES:

Hyperinsulinemia is the main driver of abundance androgens as insulin straightforwardly reenacts the activity of LH and raise the GnRH by implication . Insulin diminishes the sex chemical restricting globulin (SHBG), a really circulatory protein controlling the testosterone levels. So decreased SHBG would bring about a raised degree of free androgens that produce clinical signs like hirsutism, alopecia, and skin inflammation . Insulin obstruction can cause dyslipidemia and the patients with PCOS are at high gamble for cardiovascular sickness and diabetes . In ladies with type 1 diabetes, the commonness of PCOS is 19%,37%,41% as per NIH models, AE-PCOS definition, and ESHRE/ASRM measures separatel. As per a cross-sectional concentrate in U.S. ladies, the pervasiveness of IGT really depends on 35% and T2D depends on 10% . A few investigations uncovered that controlling insulin obstruction in the end would diminish the overabundance androgens and work on the condition.

OVULATION PROMPTING SPECIALISTS



Clomiphene citrate (CC) is the superb decision of medication for treating anovulatory clean ladies . CC expands the FSH level by hindering the estrogen receptor through a negative criticism system). It is recommended for the administration of anovulatory PCOS patients yet pregnancy rates contrast essentially as per the BMI, for BMI under 30 expanded the pace of pregnancy as well as the other way around (Chances of numerous pregnancies ultimately depend on 8% and hazard of hyperstimulation with clomiphene is nothing.

Tamoxifen acts in basically the same manner to clomiphene which is utilized to treat anovulation in patients who fall flat or not answer clomiphene citrate (Not at all like clomiphene, tamoxifen has a positive on the endometrium and cervical bodily fluid (. Because of the promising impact on uterine covering by tamoxifen, the joined investigations of clomiphene and tamoxifen uncovered an undeniable expansion in pregnancy rate . There is no fluctuation tracked down in the pace of ovulation or pregnancy with one or the other clomiphene or tamoxifen .

Letrozole is an off-mark aromatase inhibitor, that discourages the androgen to estrogen change pathway and help in folliculogenesis by invigorating FSH . Letrozole is favorable over clomiphene as estrogen receptors are not exhausted and the antiestrogenic impact on the endometrium isn't noticed . Thus, letrozole is a superior medication choice in ovulation enlistment utilized as a substitute medication to clomiphene showing comparable impacts . Studies recommend that letrozole is more viable in anovulatory fruitlessness than CC in PCOS patients . While looking at the two aromatase inhibitors that is anastrozole and letrozole, higher pregnancy rates were found with letrozole .

Gonadotropins like recombinant FSH, human menopausal gonadotropin (HMG) are the second-line decision of treatment for anovulatory fruitless PCOS ladies .Low portion FSH treatment is appropriate for ovulation acceptance and further developing pregnancy rates in PCOS patients . An interventional concentrate on demonstrated that the low-portion move forward HMG convention gave useful outcomes.. Gonadotropins can be excessively exorbitant for convenient intercourse organization, so all things considered, intrauterine insemination or in-vitro treatment is finished .

Laparoscopic medical procedure is a second-line surgery for ovulation in clomiphene-safe PCOS ladies or non-responders to clomiphene . Laparoscopic Ovarian Penetrating (LOD) is cracking the ovary on numerous occasions by laser or diathermy .The gamble of numerous pregnancy and hyperstimulation of the ovary is diminished by LOD .Albeit the drawn out hazard of LOD remembers ovarian bond for ladies .Ovarian penetrating prompts a diminishing in size and volume of the ovarian tissue, further harming the ovary yet it is closed through examinations that exhaustion in the ovarian size demonstrated ordinary working of the ovaries in PCOS ladies .

In-vitro preparation (IVF) is suggested as a third-line decision of treatment for treating fruitlessness in PCOS ladies with practically no related entanglements connected .Adjuvant metformin treatment for a brief timeframe improves pregnancy rates in PCOS ladies getting IVF . IVF includes convoluted methodology with concerning aftereffects for the most part hyperstimulation of the ovary and significant expense treatment .

WAY OF LIFE INTERCESSION

PCOS is a drawn out illness with more noteworthy possibilities of other comorbidities like sort II diabetes connected with it, so way of life change is the essential and basic methodology for execution in ladies with PCOS . Concentrates on uncovered that adjustments of the way of life, including diet, exercise, and, mentality emphatically affect body weight, insulin opposition, and testosterone levels.

DIAGNOSTIC CRITERIA

Females with polycystic ovarian syndrome have three different sets of diagnostic criteria. Each set includes various combinations of polycystic ovarian morphologic characteristics, hyperandrogenism, and ovulatory failure

All required the avoidance of extra fundamental hormonal issues or malignancies, which incorporate non-exemplary adrenal hyperplasia, thyroid sickness, androgenic growths, Cushing's condition, and hyperprolactinemia.

It is assessed that 60%-80% of PCOS females have high circling androgen levels. Clinically, hyperandrogenism can give exorbitant hair development otherwise called hirsutism, seborrhea, and skin break out. One more element is male example hair loss otherwise called androgenic alopecia . Hyperandrogenemia should be evaluated with precise androgen tests. At the point when absolute testosterone is at lower levels in females, it may not be solid. Consequently, mass spectrometry-based complete testosterone is liked. In females with PCOS, free testosterone is the most touchy test for hyperandrogenemia .

Ovulatory brokenness is many times described by unpredictable periods that happen at less than 21-day stretch or more prominent than 35-day span. The most predominant reason for oligo/amenorrhea in premenopausal females is polycystic ovarian condition (PCOS), and most of females with PCOS are insulin-safe . Weight, hyperinsulinemia, and a more focal fat circulation are all chance variables for unpredictable feminine cycle and type 2 diabetes . The component of insulin activity on the ovaries causes hyperinsulinemia, which causes unnecessary androgen combination and fringe change of androgens to estrogens in fat tissue, bringing about feminine cycle disturbances and lower origination rates. Higher estrogen levels cause feminine anomalies and anovulation by means of negative criticism at the hypothalamic-pituitary level .

Morphologically, an ovary is viewed as polycystic if at least 12 than 12 antral follicles of 2-9 mm in distance across are available in every ovary with an ovarian volume of in excess of 10 mL . Numerous females in this antral follicle count are asymptomatic determined by means of transvaginal transducers to have frequencies of 8 MHz or higher. Numerous specialists utilize the rules of 25 antral follicles rather than 12 for more prominent particularity. A talented ultrasonographer is expected for the legitimate utilization of any measure; a report of "polycystic ovaries" minus any additional capability is deficient for symptomatic purposes

Oral Contraceptives

Oral preventative pills (OCPs) can be utilized to treat females who really want to imagine. These activities advance direct hostile input on LH emission, which lessens ovarian androgen blend and hyperandrogenism. The insulin obstruction that ordinarily goes with hyperandrogenism isn't eased by the joined oral prophylactic pill. OCPs have been displayed to demolish insulin opposition. The OCPs likewise will generally improve the probability of

creating coagulatory and provocative issues in females both with and without PCOS. The OCPs utilized in PCOS are critical on the grounds that most of progestins make androgenic impacts. The androgenic impact of progestin is a huge element for the progestin part

Pharmacological mediations

The vital components of PCOS treatment incorporate side effect finding and the executives. Barrenness causing anovulation, androgen-related side effects, and unpredictable feminine cycle are a couple of examples of these.


S.N	Drugs	MOA	Adverse effects
1.	Omega-3 supplementation	C Reactive Protein(CRP) reduction	Bad breath, heartburn
2.	Insulin sensitizing drugs (Metformin HCl, pioglitazone, rosiglitazone)	Stimulating hypothalamic AMP- activated protein kinase (AMPK) and attenuates ovarian androgen production	Gastrointestinal discomfort and lactic acidosis
3.	Clomiphene Citrate	Anti-estrogen causes ovulation induction	Resistance leads to lesser clinical output
4.	Oral contraceptive pills (Progesterone therapy, Oestrogen - progesterone)	Clinically, OCPs are first line choice for the management of hirsutism in premenopausal women	Headache, breast tenderness, risk of thromboembolism and increases IR
5.	Ant androgens (Finasterid, flutamide)	Inhibits both tissue and hepatic 5- α -	Reduced libido, depression, headaches, and

Current medications used for management of PCOS

Pathophysiology

A significant part of PCOS is androgen overabundance, saw as in 60%-80% of the people who have the condition. High androgen creation has the results of hirsutism and hyperandrogenism. As a matter of fact, the most predominant irregularity saw in PCOS is hyperandrogenism, which essentially adds to the distorted chemicals that cause PCOS pathogenesis. Raised levels in the blood of free testosterone are a typical side effect of hyperandrogenism .


Essential Ovarian Pathophysiology




Pathophysiology of Polycystic Ovarian Syndrome |...

Commonly, just a single follicle goes through consecutive terminal development and ovulation because of communications impacting follicular development. At conveyance, there are something like 2-3 million early stage ovarian follicles, down from a high of around 6-7 million during mid-growth. Controlling the speed at which new early stage follicles are added to the growing pool is significant for saving richness and the ovarian hold since these follicles are then continually pulled from this pool. Follicles that are dynamic and torpid exist together in a unique harmony. Against Müllerian chemical (AMH), follicle-animating chemical (FSH), and androgens are out of equilibrium in PCOS, which causes follicular capture. Theca cells produce androgens when luteinizing chemical (LH) levels are high, yet when FSH levels are low and androgens can't be changed over completely to estradiol, no predominant follicle might be picked, prompting delayed anovulation. This balance is firmly directed by the chemical AMH, which is delivered by granulosa cells and keeps early stage follicles from developing into essential follicles. Considering this, PCOS is portrayed by an expansion in the size of the little follicles, trailed by a stop in development that causes a special polycystic structure. A few thoughts battle that follicles in an ovary with PCOS contrast essentially from those in a typical ovary.

MENSTRUAL CYCLE OF PCOS



CONCLUSIONS:

It is obvious from the survey that PCOS is a mind boggling condition. The focal component is hard to comprehend and state. In this manner no treatment can be guaranteed as an enchanted projectile as it focuses on the clinical side effects as opposed to restoring the disorder. Elective medications, for example, home grown or therapeutic plants ought to be viewed as by knowing their component of activity. Further examination with respect to pathophysiology and drugs following up on it ought to be finished for ad libbing the standing result on quiet's wellbeing. Ad libbing way of life could facilitate the PCOS related side effects.

REFERENCE

- Deans R: Polycystic ovary syndrome in adolescence. *Med Sci (Basel)*. 2019, 7:101. 10.3390/medsci7100101
- Elasam AN, Ahmed MA, Ahmed AB, Sharif ME, Abusham A, Hassan B, Adam I: The prevalence and phenotypic manifestations of polycystic ovary syndrome (PCOS) among infertile Sudanese women: a cross-sectional study. *BMC Womens Health*. 2022, 22:165. 10.1186/s12905-022-01762-6
- Bellver J, Rodríguez-Taberero L, Robles A, et al.: Polycystic ovary syndrome throughout a woman's life. *J Assist Reprod Genet*. 2018, 35:25-39. 10.1007/s10815-017-1047-7
- Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum Reprod*. 2004, 19:41-7. 10.1093/humrep/deh098
- Polycystic ovary syndrome (PCOS). (2018). Accessed: August 18, 2023: <https://drina524849529.blog/2018/08/23/olyc/>.
- McCartney CR, Marshall JC: Clinical practice. Polycystic ovary syndrome. *N Engl J Med*. 2016, 375:54-64. 10.1056/NEJMcp1514916
- Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE: Glucose intolerance in polycystic ovary syndrome—a position statement of the Androgen Excess Society. *J Clin Endocrinol Metab*. 2007, 92:4546-56. 10.1210/jc.2007-1549
- Panidis D, Tziomalos K, Papadakis E, et al.: Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome. *Hormones (Athens)*. 2015, 14:431-7. 10.14310/horm.2002.1593
- Stuart CA, Nagamani M: Insulin infusion acutely augments ovarian androgen production in normal women. *Fertil Steril*. 1990, 54:788-92.
- Azziz R, Carmina E, Dewailly D, et al.: The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. *Fertil Steril*. 2009, 91:456-88. 10.1016/j.fertnstert.2008.06.035
- Ibáñez L, Oberfield SE, Witchel S, et al.: An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. *Horm Res Paediatr*. 2017, 88:371-95. 10.1159/000479371
- Hsueh AJ, Kawamura K, Cheng Y, Fauser BC: Intraovarian control of early folliculogenesis. *Endocr Rev*. 2015, 36:1-24. 10.1210/er.2014-1020
- Franks S, Stark J, Hardy K: Follicle dynamics and anovulation in polycystic ovary syndrome. *Hum Reprod Update*. 2008, 14:367-78. 10.1093/humupd/dmn015

- Gervásio CG, Bernuci MP, Silva-de-Sá MF, Rosa-E-Silva AC: The role of androgen hormones in early follicular development. *ISRN Obstet Gynecol.* 2014, 2014:818010. 10.1155/2014/818010
- Webber LJ, Stubbs S, Stark J, Trew GH, Margara R, Hardy K, Franks S: Formation and early development of follicles in the polycystic ovary. *Lancet.* 2003, 362:1017-21. 10.1016/s0140-6736(03)14410-8
- Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T: Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. *Diabetes.* 1992, 41:1257-66. 10.2337/diab.41.10.1257
- Diamanti-Kandarakis E, Dunaif A: Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. *Endocr Rev.* 2012, 33:981-1030. 10.1210/er.2011-1034
- Geffner ME, Golde DW: Selective insulin action on skin, ovary, and heart in insulin-resistant states. *Diabetes Care.* 1988, 11:500-5. 10.2337/diacare.11.6.500
- Moller DE, Flier JS: Insulin resistance—mechanisms, syndromes, and implications. *N Engl J Med.* 1991, 325:938-48. 10.1056/NEJM199109263251307
- Badin PM, Langin D, Moro C: Dynamics of skeletal muscle lipid pools. *Trends Endocrinol Metab.* 2013, 24:607-15. 10.1016/j.tem.2013.08.001
- Brüning JC, Gautam D, Burks DJ, et al.: Role of brain insulin receptor in control of body weight and reproduction. *Science.* 2000, 289:2122-5. 10.1126/science.289.5487.2122
- Azziz R: Polycystic ovary syndrome. *Obstet Gynecol.* 2018, 132:321-36. 10.1097/AOG.0000000000002698
- Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, Hall JE: Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 1997, 82:2248-56. 10.1210/jcem.82.7.4105
- Moenter SM: Leap of faith: does serum luteinizing hormone always accurately reflect central reproductive neuroendocrine activity?. *Neuroendocrinology.* 2015, 102:256-66. 10.1159/000438790
- Cimino I, Casoni F, Liu X, et al.: Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. *Nat Commun.* 2016, 7:10055. 10.1038/ncomms10055
- Chavez JA, Summers SA: A ceramide-centric view of insulin resistance. *Cell Metab.* 2012, 15:585-94. 10.1016/j.cmet.2012.04.002
- Moret M, Stettler R, Rodieux F, et al.: Insulin modulation of luteinizing hormone secretion in normal female volunteers and lean polycystic ovary syndrome patients. *Neuroendocrinology.* 2009, 89:131-9. 10.1159/000160911
- Rashid R, Mir SA, Kareem O, et al.: Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. *Taiwan J Obstet Gynecol.* 2022, 61:40-50. 10.1016/j.tjog.2021.11.009
- Sadeghi HM, Adeli I, Calina D, et al.: Polycystic ovary syndrome: a comprehensive review of pathogenesis, management, and drug repurposing. *Int J Mol Sci.* 2022, 23:583. 10.3390/ijms23020583
- Falsetti L, Gambera A, Tisi G: Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. *Hum Reprod.* 2001, 16:36-42. 10.1093/humrep/16.1.36
- Badawy A, Elnashar A: Treatment options for polycystic ovary syndrome. *Int J Womens Health.* 2011, 3:25-35. 10.2147/IJWH.S11304
- Seli E, Duleba AJ: Should patients with polycystic ovarian syndrome be treated with metformin?. *Hum Reprod.* 2002, 17:2230-6. 10.1093/humrep/17.9.2230
- Palomba S, Falbo A, Zullo F: Management strategies for ovulation induction in women with polycystic ovary syndrome and known clomifene citrate resistance. *Curr Opin Obstet Gynecol.* 2009, 21:465-73. 10.1097/GCO.0b013e328332d188
- Kafy S, Tulandi T: New advances in ovulation induction. *Curr Opin Obstet Gynecol.* 2007, 19:248-52. 10.1097/GCO.0b013e3280c60c9a
- Casper RF, Mitwally MF: Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome. *Clin Obstet Gynecol.* 2011, 54:685-95. 10.1097/GRF.0b013e3182353d0f
- Mitwally MF, Casper RF: Single-dose administration of an aromatase inhibitor for ovarian stimulation. *Fertil Steril.* 2005, 83:229-31. 10.1016/j.fertnstert.2004.07.952
- Wang R, Kim BV, van Wely M, et al.: Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. *BMJ.* 2017, 356:j138. 10.1136/bmj.j138 SIQ